
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>L20</td><td>2</td><td>Alfacalcidol</td><td>Cholecalciferol</td><td>The risk or severity of adverse effects can be increased when Cholecalciferol is
combined with Alfacalcidol.</td></tr><tr><td>L20</td><td>2</td><td>Hydroxychloroquine</td><td>Cholecalciferol</td><td>The metabolism of Hydroxychloroquine can be decreased when combined with
Cholecalciferol.</td></tr><tr><td>L20</td><td>2</td><td>Hydroxychloroquine</td><td>Ibandronate</td><td>The risk or severity of QTc prolongation can be increased when Ibandronate is
combined with Hydroxychloroquine.</td></tr><tr><td>L20</td><td>2</td><td>Hydroxychloroquine</td><td>Insulin glulisine</td><td>The therapeutic efficacy of Insulin glulisine can be increased when used in
combination with Hydroxychloroquine.</td></tr><tr><td>L20</td><td>2</td><td>Insulin glulisine</td><td>Amlodipine</td><td>The risk or severity of hypoglycemia can be increased when Amlodipine is
combined with Insulin glulisine.</td></tr><tr><td>L20</td><td>2</td><td>Rilpivirine</td><td>Amlodipine</td><td>The metabolism of Rilpivirine can be decreased when combined with Amlodipine.</td></tr><tr><td>L20</td><td>2</td><td>Rilpivirine</td><td>Hydroxychloroquine</td><td>The metabolism of Hydroxychloroquine can be decreased when combined with
Rilpivirine.</td></tr><tr><td>L20</td><td>2</td><td>Rilpivirine</td><td>Ibandronate</td><td>The risk or severity of QTc prolongation can be increased when Ibandronate is
combined with Rilpivirine.</td></tr><tr><td>L20</td><td>2</td><td>Tenofovir alafenamide</td><td>Amlodipine</td><td>The metabolism of Tenofovir alafenamide can be decreased when combined with
Amlodipine.</td></tr><tr><td>L20</td><td>2</td><td>Tenofovir alafenamide</td><td>Ibandronate</td><td>The risk or severity of nephrotoxicity and hypocalcemia can be increased when
Tenofovir alafenamide is combined with Ibandronate.</td></tr></tbody></table></div>
